Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy right now. ATAI Life Sciences holds a Strong Buy consensus from 8 analysts, with a 12‑month average target of ...
WCIV

North Charleston researchers launch LSD clinical trial to treat severe anxiety

A new clinical trial underway in the Lowcountry is drawing attention for its unconventional — and potentially groundbreaking ...
Psychology Today

Why Depression May Be In Your Bones

Your skeleton is 20 pounds of miracle, contributing to your mood, memory, and metabolism. Learn why better mental health may, ...
TipRanks on MSN

Lipocine advances phase 3 trial for PPD treatment

Lipocine ( ($LPCN) ) has shared an announcement. On December 16, 2025, Lipocine announced that its Phase 3 clinical trial for LPCN 1154, an oral ...
Healio

Q&A: What to know about the benefits and risks of women’s supplement use

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Courtney Cameron, PharmD, BCACP, about widespread availability of ...
Le Lézard

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, today announced ...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

The newly granted U.S. patent, No. 12,492,178, includes claims to the drug substance of EMP-01, and is expected to provide exclusivity through 2043. This patent identifies a highly-crystalline, ...